ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid D…

2024 ASH Annual Meeting Insights Hub

H. Fernandez

Summary of Recent Updates in MDS

Vanderbilt University Medical Center (VUMC)

S. Ball

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Differentiation of CHIP, ICUS, CCUS, MDS, and VEXAS Syndrome

MyCancerHaven

R. Vij, S. Abedin

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

ASH 2024 Insights: Secondary Heme Malignancies in Myeloma Post-CAR-T…

2024 ASH Annual Meeting Insights Hub

J. Waldschmidt

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

L. Banaszak

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Rush University Medical Center

E. Bhaimia

Current and Emerging Treatment Approaches for Patients With AML or M…

University of Miami Sylvester Comprehensive Cancer Center

S. Venugopal

Chronic GvHD: Main Complications After ASCT

Steven Pavletic

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based GvHD Pr…

2024 ASCO® Annual Meeting Insights Hub

M. Al Malki

Allo-HSCT Conditioning Regimens: Current Status and Future Directions

Rush University Medical Center

C. Brunstein

ASH 2024 Insights: Ven + HMA vs. HMA Alone in TP53m HR-MDS - Real-Wo…

2024 ASH Annual Meeting Insights Hub

T. Badar

Bone Marrow Failure: The Importance of Mutational Testing

Rush University Medical Center

J. Shammo

Making Sense of the New Classification Systems for MDS in 2024

Moffitt Cancer Center

R. Komrokji